Dequanter Didier, Dok Ruveyda, Koolen Louet, Vander Poorten Vincent, Nuyts Sandra
Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, Belgium.
Department of Head and Neck Surgery, CHU Saint Pierre, Brussels, Belgium.
Front Oncol. 2017 May 9;7:84. doi: 10.3389/fonc.2017.00084. eCollection 2017.
To date, no reliable prognostic biological marker for all squamous cell carcinoma located in different subsites of the head and neck region has been identified and used in daily routine. In line with our previous studies, in which we showed a role of glutathione and associated enzymes as potential biological markers, we investigated the relationship between GPx1 and prognosis of head and neck squamous cell carcinoma.
The association between GPx1 and patient and tumor related factors were investigated in 87 pretreatment biopsies from head and neck cancer patients treated by (chemo)radiation. Moreover, the influence of GPx1 expression on outcome parameters was assessed.
A significant difference was found in the T-stage between the low and high-expressing GPx1 groups. About 75% of the T3-T4 tumors were considered GPx1 low-expressing tumors, while low GPx1 expression was only seen in 25% of the T1-T2 tumors. There was also a significant difference found between the groups when looking at the different tumor sites. Local control, locoregional control, disease-free survival, and overall survival were the same in both groups. All these results indicate that GPx1 expression does not influence the radiotherapy response nor survival.
迄今为止,尚未发现一种可靠的、可用于日常临床的、针对所有位于头颈部不同亚部位的鳞状细胞癌的预后生物学标志物。与我们之前的研究一致,在之前的研究中我们表明谷胱甘肽及相关酶作为潜在生物学标志物发挥了作用,我们研究了GPx1与头颈部鳞状细胞癌预后之间的关系。
在87例接受(化疗)放疗的头颈部癌症患者的治疗前活检样本中,研究了GPx1与患者及肿瘤相关因素之间的关联。此外,评估了GPx1表达对预后参数的影响。
在GPx1低表达组和高表达组之间,T分期存在显著差异。约75%的T3 - T4期肿瘤被认为是GPx1低表达肿瘤,而只有25%的T1 - T2期肿瘤出现低GPx1表达。在观察不同肿瘤部位时,两组之间也存在显著差异。两组的局部控制、区域控制、无病生存率和总生存率相同。所有这些结果表明,GPx1表达不影响放疗反应和生存率。